» Articles » PMID: 15451803

Impact of Prehospital Thrombolysis for Acute Myocardial Infarction on 1-year Outcome: Results from the French Nationwide USIC 2000 Registry

Overview
Journal Circulation
Date 2004 Sep 29
PMID 15451803
Citations 25
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Limited data are available on the impact of prehospital thrombolysis (PHT) in the "real-world" setting.

Methods And Results: Of 443 intensive care units in France, 369 (83%) prospectively collected all cases of infarction (< or =48 hours of symptom onset) in November 2000; 1922 patients (median age, 67 years; 73% men) with ST-segment-elevation infarction were included, of whom 180 (9%) received intravenous thrombolysis before hospital admission (PHT). Patients with PHT were younger than those with in-hospital thrombolysis, primary percutaneous interventions, or no reperfusion therapy. Median time from symptom onset to hospital admission was 3.6 hours for PHT, 3.5 hours for in-hospital lysis, 3.2 hours for primary percutaneous interventions, and 12 hours for no reperfusion therapy. In-hospital death was 3.3% for PHT, 8.0% for in-hospital lysis, 6.7% for primary percutaneous interventions, and 12.2% for no reperfusion therapy. One-year survival was 94%, 89%, 89%, and 79%, respectively. In a multivariate analysis of predictors of 1-year survival, PHT was associated with a 0.49 relative risk of death (95% CI, 0.24 to 1.00; P=0.05). When the analysis was limited to patients receiving reperfusion therapy, the relative risk of death for PHT was 0.52 (95% CI, 0.25 to 1.08; P=0.08). In patients with PHT admitted in < or =3.5 hours, in-hospital mortality was 0% and 1-year survival was 99%.

Conclusions: The 1-year outcome of patients treated with PHT compares favorably with that of patients treated with other modes of reperfusion therapy; this favorable trend persists after multivariate adjustment. Patients with PHT admitted very early have a very high 1-year survival rate.

Citing Articles

Evolution of REperfusion Strategies and impact on mortality in Old and Very OLD STEMI patients. The RESOVOLD-e-MUST study.

Lapostolle F, Petrovic T, Moiteaux B, Loyeau A, Boche T, Kadji Kalabang R Age Ageing. 2024; 53(1).

PMID: 38167925 PMC: 10762506. DOI: 10.1093/ageing/afad215.


Early Changes in Acute Myocardial Infarction in Pigs: Achieving Early Detection with Wearable Devices.

Li K, Morales-Garza M, Cardoso C, Moctezuma-Ramirez A, Burman A, Titus J Diagnostics (Basel). 2023; 13(6).

PMID: 36980316 PMC: 10046897. DOI: 10.3390/diagnostics13061006.


The Effects of the SARS-CoV-2 Virus on the Cardiovascular System and Coagulation State Leading to Cardiovascular Diseases: A Narrative Review.

Bhat R, Maqbool S, Rathi A, Ali S, Hussenbocus Y, Wentao X Inquiry. 2022; 59:469580221093442.

PMID: 35613600 PMC: 9149622. DOI: 10.1177/00469580221093442.


Collaborative Heart Attack Management Program (CHAMP): use of prehospital thrombolytics to improve timeliness of STEMI management in British Columbia.

Guy A, Gabers N, Crisfield C, Helmer J, Peterson S, Ganstal A BMJ Open Qual. 2021; 10(4).

PMID: 34872989 PMC: 8650474. DOI: 10.1136/bmjoq-2021-001519.


Time is Muscle.

Abreu L Arq Bras Cardiol. 2019; 112(4):408-409.

PMID: 30994719 PMC: 6459437. DOI: 10.5935/abc.20190059.